ライフサイエンスコーパス: hepatitis A vaccine

1 HPV 16/18 AS04-adjuvanted vaccine or control hepatitis A vaccine.

2 who responded to a 3-dose primary series of hepatitis A vaccine.

3 l subjects reported a willingness to receive hepatitis A vaccine.

4 iting fewer injection-site symptoms than the hepatitis A vaccine (19.8% compared with 37.5%).

5 ere vaccinated with two doses of inactivated hepatitis A vaccine, 6 months apart.

6 Persistence of seropositivity conferred by hepatitis A vaccine administered to children <2 years of

7 Hepatitis A vaccine administered to persons after exposu

8 Among these contacts, 568 received hepatitis A vaccine and 522 received immune globulin.

9 s A/hepatitis B vaccine to each other and to hepatitis A vaccine and hepatitis B vaccine given separa

10 of hepatitis A in both groups indicate that hepatitis A vaccine and immune globulin provided good pr

11 Hepatitis A vaccines are highly immunogenic in healthy p

12 60 children with 162 household contacts, and hepatitis A vaccine as a control was administered to 67

13 s an adjuvant; control subjects received the hepatitis A vaccine, at a dose of 720 enzyme-linked immu

14 ricomponent acellular pertussis vaccine or a hepatitis A vaccine (control) and were monitored for 2.5

15 age, in a 1:1 ratio, to receive the QIV or a hepatitis A vaccine (control).

16 were immunized with 13-valent PCV (PCV13) or hepatitis A vaccine (control).

17 The seropositivity induced by hepatitis A vaccine given to children <2 years of age pe

18 ized into three groups to receive a two-dose hepatitis A vaccine: group 1 at 6 and 12 months, group 2

19 Since the mid-1990s, hepatitis A vaccine has been recommended for US children

20 Hepatitis A vaccine has similar efficacy to immune globu

21 combined with the availability of effective hepatitis A vaccines have dramatically reduced the burde

22 rus, pneumococcal, polio, meningococcal, and hepatitis A vaccines have taken place, which will have m

23 In this study, AE profiles induced by hepatitis A vaccine (Havrix), hepatitis B vaccine (Enger

24 es of hepatitis A, we assessed the impact of hepatitis A vaccine in Alaska Native persons.

25 ssess the safety and efficacy of inactivated hepatitis A vaccine in OLT recipients.

26 safety and immunogenicity of an inactivated hepatitis A vaccine in patients with CLD with that in he

27 ase have been confirmed, and the efficacy of hepatitis A vaccines in these patients has been proven.

28 The response to the hepatitis A vaccine is optimal when targeted to patients

29 SmithKline, Rixensart, Belgium) or a control hepatitis A vaccine (modified preparation of Havrix, Gla

30 04 candidate vaccine (n = 1088) or a control hepatitis A vaccine (n = 1101) over 6 months.

31 tivized measures (largest difference was for hepatitis A vaccine: odds ratio, 0.34; 99.88% CI, 0.31-0

32 receive one standard age-appropriate dose of hepatitis A vaccine or immune globulin within 14 days af

33 , the first dose was 720 ELISA units (EU) of hepatitis A vaccine, readministered at 1 and 12 months a

34 3%) seroconverted after a single dose of the hepatitis A vaccine than did subjects with chronic hepat

35 Hepatitis A vaccine uptake among people with chronic liv

36 16 and 18 AS04-adjuvanted vaccine or control hepatitis A vaccine, using a blocked randomisation metho

37 (n = 70) 4 weeks after a dose of inactivated hepatitis A vaccine (VAQTA).

38 gned (1:1) to HPV-16/18 vaccine or a control hepatitis A vaccine, via an internet-based central rando

39 25-, 50-, and 100-U doses of an inactivated hepatitis A vaccine was examined in 358-seronegative vol

40 In this population, hepatitis A vaccine was highly effective in preventing d

41 In conclusion, hepatitis A vaccine was well tolerated and induced a sat

42 y objective was to compare the safety of the hepatitis A vaccine with that of a commercial hepatitis